I’m finding the controversy over the Epipen price increases fascinating, because of its hoist-by-their-own-petard quality.
When Mylan acquired Epipen in 2007, it wasn’t a particularly popular product. Then Mylan started a heavy marketing push, which included increasing awareness of the dangers of allergies, publicizing how Epipen could save lives in emergencies, and lobbying for legislation requiring that Epipens be stocked in public places as an emergency health device, like defibrillators. Because Mylan did a tremendous job of persuading the public that the Epipen was a critical medical device, it was able to raise prices dramatically – and now, having convinced everyone and his mother that Epipens are indispensable, the company is getting backlash for price gouging on this life-saving technology (not to mention becoming the target of investigations and lawsuits over, among other things, Medicaid fraud and state law antitrust violations).
Haskell previously posted about the Epipen situation, and connected the issue to the shareholder wealth maximization norm in corporate law. Going further, he asked whether, from a policy perspective, we particularly want to encourage some other sort of stakeholder model for the healthcare industry.
I guess my point is, the issue is not just price increases; it
